🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHeart rate increase on GLP-1 — November 2025 Page 6

Heart rate increase on GLP-1 — November 2025

Dr.ObesityMed Thu, May 30, 2024 at 5:58 AM 31 replies 2,498 viewsPage 6 of 7
TomTeleRx
Member
189
678
Feb 2025
Delaware
Jun 5, 2024 at 6:51 PM#26
PeptideChemSF said:
Senior perspective on cardiovascular risk: I'm 70 years old and started this journey skeptically.

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

Last edited: Jun 5, 2024 at 7:51 PM
4 2pete_manc_UK, anna.melb_AU, mark_tokyo and 1 other
Reply Quote Save Share Report
mark_tokyo
Member
456
1,890
Jun 2024
Tokyo, JP
Jun 6, 2024 at 1:11 PM#27
PeptideChemSF said:
Senior perspective on cardiovascular risk: I'm 70 years old and started this journey skeptically.
PeptideChemSF said:
...we don't know the long-term effects of cardiovascular risk...

This is a fair point, and I think intellectual honesty requires acknowledging it. GLP-1 agonists in their current form have ~8-10 years of human exposure data. That's not nothing, but it's not 30+ years either.

However: the risk-benefit calculation should also consider the KNOWN long-term effects of untreated obesity — diabetes, cardiovascular disease, cancer, joint destruction, reduced lifespan by 5-10 years.

Uncertainty about GLP-1 long-term safety vs certainty about obesity consequences. The calculus seems clear to me, but reasonable people can disagree.

5 3bri_stats, pete_manc_UK, anna.melb_AU and 2 others
Reply Quote Save Share Report
MarkLI_maint
Member
534
2,345
Jun 2024
Long Island, NY
Jun 7, 2024 at 7:30 AM#28
PeptideChemSF said:
Senior perspective on cardiovascular risk: I'm 70 years old and started this journey skeptically.

This answered a question I did not know how to ask. Printing the relevant bit and taking it with me.

Last edited: Jun 7, 2024 at 12:30 PM
6 4HPLC_Greg, LibrarianMeg, bri_stats and 3 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
VanRx_Mike
Member
678
2,890
May 2024
Vancouver, CA
Jun 8, 2024 at 1:49 AM#29

Adding the clinical framing, because it changes how the question reads.

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -1.6 lbs/week average
Fasting glucose (finger stick): stable at 83 mg/dL
Blood pressure (home): 116/73 average
Resting heart rate: 63 bpm (down from 79)
Waist circumference: down 13 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

7 5Dr.Martinez, mike_mod, SarahChen_PharmD and 4 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Jun 8, 2024 at 8:07 PM#30
mark_tokyo said:
PeptideChemSF said: ...we don't know the long-term effects of cardiovascular risk...

6 month update on cardiovascular risk: down 56 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

29 2A1cHero_PHX, Dr.RenalNash, LipidDoc_ATL and 26 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register